IFRX (InflaRx NV) Cyclically Adjusted Book per Share: $3.42 (As of Mar. 2026)


IFRX InflaRx NV IFRX
31 GF Score
Price $2.24
! 5 Warning Signs
View Full Analysis

What is InflaRx NV Cyclically Adjusted Book per Share?

InflaRx NV IFRX -3.03% 31 Cyclically Adjusted Book per Share is $3.42 as of Mar. 2026. GuruFocus rates IFRX with a GF Score™ of 31/100. The stock has 5 warning signs investors should review.

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

InflaRx NV's adjusted book value per share for the three months ended in Mar. 2026 was $0.590. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is $3.42 for the trailing ten years ended in Mar. 2026.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Book Growth Rate using Cyclically Adjusted Book per Share data.

As of today (2026-07-01), InflaRx NV's current stock price is $2.235. InflaRx NV's Cyclically Adjusted Book per Share for the quarter that ended in Mar. 2026 was $3.42. InflaRx NV's Cyclically Adjusted PB Ratio of today is 0.65.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of InflaRx NV was 0.68. The lowest was 0.00. And the median was 0.00.


InflaRx NV  (NAS:IFRX) Cyclically Adjusted Book per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Book per Share may underestimate the company's equity. Cyclically Adjusted PB Ratio can seem to be too high even the actual PB Ratio is low.

For the Cyclically Adjusted PB Ratio, the book value of the past 10 years are inflation-adjusted and averaged. The result is used for P/B calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PB Ratio is also called CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

InflaRx NV's Cyclically Adjusted PB Ratio of today is calculated as

Cyclically Adjusted PB Ratio=Share Price/Cyclically Adjusted Book per Share
=2.235/3.42
=0.65

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 11 years, the highest Cyclically Adjusted PB Ratio of InflaRx NV was 0.68. The lowest was 0.00. And the median was 0.00.


Be Aware

Cyclically Adjusted PB Ratio works better for cyclical companies. It gives you a better idea on the company's real book value.


InflaRx NV Cyclically Adjusted Book per Share Related Terms


InflaRx NV Cyclically Adjusted Book per Share Historical Data

* Premium members only.

The historical data trend for InflaRx NV's Cyclically Adjusted Book per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

InflaRx NV Cyclically Adjusted Book per Share Chart

InflaRx NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted Book per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 3.32

InflaRx NV Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Cyclically Adjusted Book per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 3.32 3.42

IFRX vs BCYC, ELDN, ZNTL: Cyclically Adjusted Book per Share Comparison

For the Biotechnology subindustry, InflaRx NV's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


InflaRx NV Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, InflaRx NV's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where InflaRx NV's Cyclically Adjusted PB Ratio falls into.


IFRX
31GF Score
InflaRx NV IFRX
Cyclically Adjusted Book per Share is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

InflaRx NV Cyclically Adjusted Book per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Book per Share and the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years.

What is Cyclically Adjusted Book per Share? How do we calculate Cyclically Adjusted Book per Share?

Cyclically Adjusted Book per Share is the average of the inflation adjusted Book Value per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Book per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the book value per share from 2001 through 2010.

We adjusted the 2001 book value per share data with the total inflation from 2001 through 2010 to the equivalent book value in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's book value is $1 a share in 2001, then the 2001's equivalent book value in 2010 is $1.4 a share. If Wal-Mart's book value is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 book value in 2010 is $1.35. So on and so forth, you get the equivalent book value per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, InflaRx NV's adjusted Book Value per Share data for the three months ended in Mar. 2026 was:

Adj_Book= Book Value per Share /CPI of Mar. 2026 (Change)*Current CPI (Mar. 2026)
=0.59/131.2583*131.2583
=0.590

Current CPI (Mar. 2026) = 131.2583.

InflaRx NV Quarterly Data

Book Value per Share CPI Adj_Book
201606 0.000 100.717 0.000
201609 0.000 101.017 0.000
201612 -1.157 101.217 -1.500
201703 0.000 101.417 0.000
201706 -1.568 102.117 -2.015
201709 -1.840 102.717 -2.351
201712 5.935 102.617 7.592
201803 5.801 102.917 7.398
201806 7.365 104.017 9.294
201809 7.133 104.718 8.941
201812 6.633 104.217 8.354
201903 6.353 104.217 8.001
201906 5.695 105.718 7.071
201909 5.196 106.018 6.433
201912 4.561 105.818 5.658
202003 4.297 105.718 5.335
202006 3.906 106.618 4.809
202009 3.743 105.818 4.643
202012 3.356 105.518 4.175
202103 3.741 107.518 4.567
202106 3.370 108.486 4.077
202109 3.068 109.435 3.680
202112 2.691 110.384 3.200
202203 2.370 113.968 2.730
202206 2.442 115.760 2.769
202209 2.227 118.818 2.460
202212 2.094 119.345 2.303
202303 1.879 122.402 2.015
202306 2.293 123.140 2.444
202309 2.139 124.195 2.261
202312 1.900 123.773 2.015
202403 1.749 125.038 1.836
202406 1.502 125.882 1.566
202409 1.230 126.198 1.279
202412 1.084 127.041 1.120
202503 1.124 127.779 1.155
202506 0.971 128.412 0.993
202509 0.786 129.255 0.798
202512 0.673 129.361 0.683
202603 0.590 131.258 0.590

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

What does a Cyclically Adjusted Book per Share of $3.42 mean?
InflaRx NV (IFRX) has a Cyclically Adjusted Book per Share of $3.42 as of Mar. 2026. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on InflaRx NV and its competitors.
Is InflaRx NV's Cyclically Adjusted Book per Share too high?
InflaRx NV's current Cyclically Adjusted Book per Share is $3.42. Overall, InflaRx NV has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does InflaRx NV's Cyclically Adjusted Book per Share compare to BCYC and ELDN?
InflaRx NV's Cyclically Adjusted Book per Share of $3.42 can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted Book per Share for a Biotechnology company?
A good Cyclically Adjusted Book per Share depends on the Biotechnology industry context. However, Cyclically Adjusted Book per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted Book per Share mean?
A high Cyclically Adjusted Book per Share can signal that a stock is expensive relative to its fundamentals. Cyclically adjusted book value per share represents the company's inflation-adjusted book value per share over a 10-year period. View historical data on InflaRx NV and its competitors. InflaRx NV's current Cyclically Adjusted Book per Share is $3.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is InflaRx NV stock overvalued right now?
InflaRx NV (IFRX) has a current Cyclically Adjusted Book per Share of $3.42. The current Cyclically Adjusted Book per Share is $3.42. InflaRx NV's overall GF Score™ is 31/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted Book per Share calculated?
Cyclically Adjusted Book per Share is calculated from a company's financial statements. For InflaRx NV (IFRX), the current Cyclically Adjusted Book per Share is $3.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

InflaRx NV Business Description

Other Exchanges IF0:Germany
Address Winzerlaer Strasse 2, Jena, DEU, 07745
InflaRx NV is a biopharmaceutical company applying proprietary technologies to discover, develop and commercialize potent and specific inhibitors of the complement activation factor known as C5a and its receptor C5aR. With its therapeutic product candidates, vilobelimab and izicopan, the company targets C5a and its receptor C5aR to selectively inhibit the powerful inflammatory response observed in a wide variety of autoimmune and other inflammatory diseases elicited through C5a/C5aR activation. Its product candidate, GOHIBIC (vilobelimab), is a novel intravenously delivered anti-C5a monoclonal antibody that selectively binds to free C5a and has demonstrated disease-modifying clinical activity and tolerability in multiple clinical settings.
31GF Score

Get the complete analysis for IFRX

Cyclically Adjusted Book per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$2.24
Price